Provided is a phenolic hydroxy group-containing resin having sufficient solubility in organic solvents, having excellent infiltratability into microscopic spaces because of having low viscosity and low polarity, and being capable of being used for ultrafine wiring pattern formation. Specifically, provided is a phenolic hydroxy group-containing resin containing one or more phenolic hydroxy group-containing compounds (1) selected from the group consisting of a compound (1) represented by Structural Formula (1) below and a compound (1) represented by Structural Formula (1) below.

##STR00001##

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the -secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of -amyloid aggregates.

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the -secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of -amyloid aggregates.

The present disclosure provides processes for the preparation of a compound of formula:

##STR00001##

which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.

The present disclosure provides processes for the preparation of a compound of formula:

##STR00001##

which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the -secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of -amyloid aggregates.

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the -secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of -amyloid aggregates.

In some embodiments, the compositions and methods relate to compounds isolated from plants in the Salviniaceae family, pharmaceutical compositions comprising the same, and methods of using the same.

In some embodiments, the compositions and methods relate to compounds isolated from plants in the Salviniaceae family, pharmaceutical compositions comprising the same, and methods of using the same.

The present disclosure provides processes for the preparation of a compound of formula: ##STR00001##
which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.